P-glycoprotein expression and function in patients with temporal lobe epilepsy: A case-control study

The Lancet Neurology

Volumn 12, Issue 8, 2013, Pages 777-785

  Feldmann, Maria ^a,b   Asselin, Marie Claude ^b   Liu, Joan ^a   Wang, Shaonan ^b   McMahon, Adam ^b   Anton Rodriguez, José ^b   Walker, Matthew ^a,b   Symms, Mark ^a   Brown, Gavin ^b   Hinz, Rainer ^b   Matthews, Julian ^b   Bauer, Martin ^d   Langer, Oliver ^d,e   Thom, Maria ^a   Jones, Terry ^f   Vollmar, Christian ^a,c   Duncan, John S ^a   Sisodiya, Sanjay M ^a,c   Koepp, Matthias J ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c EPILEPSY SOCIETY   (United Kingdom)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^f PET Research Advisory Company   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUSIFORM GYRUS; GRAY MATTER; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; INFERIOR TEMPORAL GYRUS; MALE; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEIZURE; TEMPORAL LOBE EPILEPSY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CALCIUM CHANNEL BLOCKERS; CARBON ISOTOPES; CASE-CONTROL STUDIES; EPILEPSY, TEMPORAL LOBE; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; VERAPAMIL; YOUNG ADULT;

EID: 84880325687     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70109-1     Document Type: Article

References (30)

1. Kwan P, Brodie M Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-331.
2. Kwan P, Arzimanoglou A, Berg A, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
3. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995, 36:1-6.
4. Volk HA, Loescher W Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005, 128:1358-1368.
5. van Vliet E, van Schaik R, Edelbroek P, et al. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 2007, 322:141-147.
6. Bankstahl J, Loescher W Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res 2008, 82:70-85.
7. Brandt C, Bethmann K, Gastens AM, Loescher W The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 2006, 24:202-211.
8. Aronica E, Özbas-Gerçeker F, Redeker S, et al. Expression and cellular distribution of high- and low-affinity neurotrophin receptors in malformations of cortical development. Acta Neuropathol 2004, 108:422-434.
9. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002, 125:22-31.
10. Liu J, Thom M, Catarino C, et al. Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 2012, 135:3115-3133.
11. Lubberink M, Luurtsema G, van Berckel BN, et al. J Cereb Blood Flow Metab 2007, 27:424-433.
12. Giacomini K, Huang S, Tweedie D, et al. Membrane transporters in drug development. Rev Drug Discov 2010, 9:215-236.
13. Wagner C, Feuerstein T, Karch R, et al. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)[11C]verapamil and PET. J Nucl Med 2009, 50:1954-1961.
14. Kuntner C, Bankstahl J, Bankstahl M, et al. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging 2010, 37:942-953.
15. Bankstahl J, Bankstahl M, Kuntner C, et al. A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci 2011, 31:8803-8811.
16. Anton-Rodriguez JM, Sibomana M, Walker MD, et al. Investigation of motion induced errors in scatter correction for the hrrt brain scanner. Nuclear Science Symposium Conference Record (NSS/MIC) 2010, 2935-2940. IEEE.
17. Feng D, Wang Z, Huang SC A study on statistically reliable and computationally efficient algorithms for generating local cerebral blood flow parametric images with positron emission tomography. IEEE Trans Med Imaging 1993, 2:182-188.
18. Abrahim A, Luurtsema G, Bauer M, et al. Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging 2008, 35:116-123.
19. Muzi M, Mankoff DA, Link JM, et al. Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans. J Nucl Med 2009, 50:1267-1275.
20. Friston KJ Testing for anatomically specified regional effects. Hum Brain Mapp 1997, 5:133-136.
21. Langer O, Bauer M, Hammers A, et al. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia 2007, 48:1774-1784.
22. Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, Marson AG Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol 2012, 11:331-340.
23. Zhang C, Zuo Z, Kwan P, Baum L In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 2011, 52:1894-1904.
24. Baltes S, Fedrowitz M, Tortós CL, Potschka H, Loescher W Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Thers 2007, 320:331-343.
25. Lombardo L, Pellitteri R, Balazy M, Cardile V Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res 2008, 5:82-92.
26. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
27. Westover MB, Cormier J, Bianchi MT, et al. Revising the "Rule of Three" for inferring seizure freedom. Epilepsia 2012, 53:368-376.
28. Bauer M, Zeitlinger M, Karch R, et al. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther 2012, 91:227-233.
29. Baron JC, Roeda D, Munari C, Crouzel C, Chodkiewicz JP, Comar D Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans. Neurology 1983, 33:580-585.
30. Potschka H Modulating P-glcoprotein regulation: future perspectives for pharmacoresistant epilepsies?. Epilepsia 2010, 51:1333-1347.